Lymphoma Rounds: Washington, D.C.
Washington Marriott Georgetown Hotel (click here for directions)
1221 22nd Street NW
Washington, D.C. 20037
Wednesday, March 21, 2018
6:00 – 8:30 PM
Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Piper Harmon, firstname.lastname@example.org. Exhibit opportunities are also available, however, space is limited.
|6:00PM||Registration and Networking Dinner Reception|
|Piper Harmon, Lymphoma Research Foundation|
|7:00 PM||A Case of a CLL Patient|
|Mayur Narkhede, MD, MedStar Georgetown University Hospital|
|Chaitra Ujjani, MD, MedStar Georgetown University Hospital|
|7:30 PM||Young Patients with Untreated Follicular Lymphoma|
|Andy Itsara, MD, PhD, National Cancer Institute|
|Mark Roschewski, MD, National Cancer Institute|
|8:00 PM||Anti-CD19 CAR T-Cell Therapy in a Patient with Mantle Cell Lymphoma|
|Samah Nassereddine, MD, George Washington University Cancer Center|
|Kieron Dunleavy, MD, George Washington University Cancer Center|
ABOUT THE PROGRAM
The Lymphoma Research Foundation’s Washington DC Lymphoma Rounds program provides a forum for healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Participants will network, share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the Washington DC area.
At the conclusion of this educational activity, the participant should be better able to:
- Summarize the latest developments in lymphoma diagnosis, treatment and management.
- Apply best practices for treating lymphoma patients.
- Inform patients about potential clinical trial opportunities.
- Establish a network of health care professionals who work with lymphoma patients.
This activity is supported by educational grants from:
AbbVie, Celgene, Genentech, Juno Therapeutics, Kite Pharma, Pharmacyclics LLC and Janssen Biotech, Inc., Seattle Genetics, Spectrum Pharmaceuticals, Teva Pharmaceuticals Industries, LTD and TG Therapeutics